Atrium Therapeutics RNA
Drug Manufacturers - General, Healthcare
$8.55
+3.39%
- Market cap
- $146.3M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q1 FY25 | Q2 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| $1.6M | $3.8M | $19.6M | $3M | |
| R&D | $6.9M | $13.3M | $16.7M | $15.3M |
| SG&A | $2.1M | $3.4M | $20.3M | $10.3M |
| −$7.5M | −$12.9M | −$17.3M | −$22.6M | |
| Net income | −$7.4M | −$12.9M | −$16.6M | −$20.2M |
| −$0.44 | −$0.75 | −$0.97 | −$1.18 | |
| 17.1M | 17.1M | 17.1M | 17.1M |
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Atrium Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| RNAAtrium Therapeutics | $146.3M | n/m | n/a | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $211.5M | 11.9× | 20.2× | 0.4× | +7% | 3.7% | |
| LFVNLifevantage | $73.5M | 14.7× | 19.4× | 0.4× | −20% | 2.8% | |
| SPROSpero Therapeutics | $60.6M | 9.5× | 9.5× | 1.3× | −3% | 15.7% | |
| CRMDCorMedix | $420.1M | 2.5× | 4.0× | 0.9× | +281% | 40.5% | |
| ATNMActinium Pharmaceuticals | $45M | 4.0× | 3.3× | n/m | n/m | n/m | |
| ARVNArvinas | $491.7M | 47.0× | 50.5× | 1.6× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $525.5M | 19.6× | 12.3× | 2.3× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.8× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $599.8M | 10.9× | 12.2× | 4.4× | +119% | 42.8% | |
| COLLCollegium Pharmaceutical | $770.9M | 19.1× | 19.1× | 1.0× | +14% | 5.9% | |
| Peer median | $455.9M | 11.4× | 13.5× | 1.3× | +7% | 11.6% |
More on Atrium Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .